Oral Poliomyelitis Vaccine, Live, Attenuated (OPV) [Discontinued in SA Market]

Registered South African indications:

• Prevention of poliomyelitis

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Hypersensitivity to neomycin, streptomycin and polymyxin B, or serious reactions after previous administration of an oral poliomyelitis vaccine
• Congenital or acquired immunodeficiency in the subject to be vaccinated or in subject in close contact with the subject to be vaccinated
• Immune deficiencies which include, human immunodeficiency virus (HIV), immunodepressant treatments and progressive malignant disease. In such cases, it is advisable to use inactivated poliomyelitis vaccine

Cautions

• Pregnancy
• Renal impairment
• Hepatic impairment
• Administration within 3 months of prior immunoglobulin use

Not indicated for use in adults

Paed. forms avail. in SA and covered in this monograph: sol

Prevention of poliomyelitis

• Oral (sol): 2 drops, given at birth and 6 weeks; Booster to be given at 5 years (EML 2013)

Pregnancy

• FDA Pregnancy Category Not Rated (NR)

Breastfeeding

• Not indicated for use in adults

Renal Impairment

• Caution; no information available

Hepatic Impairment

• Caution; no information available

Elderly

• Not indicated for use in geriatric patients

Central Nervous System Disorders

• Malaise
• Headache
• Vaccine-associated poliomyelitis

Immune, Blood and Lympathic System Disorders

• Hypersensitivity 
• Fever

No information available

None routine

Oral polio vaccine (OPV) induces protective antibodies, reducing intestinal and pharyngeal excretion of poliovirus. OPV administration simulates natural infection, inducing active mucosal and systemic immunity against poliovirus types 1, 2, and 3.

Drops  0.1ml

• OPV-Merieux (Sanofi) originator